CERAD, The Consortium to Establish a Registry for Alzheimer’s Disease
 
CERAD Neuropathology Assessment

The CERAD neuropathology criteria are widely used in the US and abroad for studies of Alzheimer’s disease and other dementias of the elderly. This assessment was developed to fulfill the following aims and purposes:

  • To establish accurate, reliable, and standardized neuropathological criteria for the diagnosis of Alzheimer’s disease (AD) and other dementias;
  • To develop a practical protocol for postmortem examination of the brain and provide standard, reliable measures for determining the neuropathological spectrum and heterogeneity of Alzheimer’s disease and other dementias;
  • To extend the CERAD assessments to include dementias associated with other disorders such as vascular disease, Parkinson’s disease, alcoholism, and depression;
  • To establish a data base for pooling the neuropathological findings of Alzheimer’s disease and other dementias with clinical information on demented and cognitively normal subjects.

The Neuropathology assessment packet includes the following data forms:
A. Demographic Data
B. Clinical History
C. Gross Examination of the Brain
D. Cerebral Vascular Disease: Gross Findings
E. Microscopic Vascular Findings
F. Major Non-vascular Microscopic Findings
G. Microscopic Evaluation of Hippocampus and Neocortex
H. Assessment of Neurohistological Findings
I. Neuropathological Diagnosis
J. Final Assessment

This assessment packet includes a detailed manual, The CERAD Guide to the Neuropathological Assessment of Alzheimer’s Disease and Other Dementias.

See the CERAD list of publications on neuropathological findings in AD.

For information regarding purchase of this assessment material, check the Order Form.

Download Printable version of this page.


Center for the Study of Aging and Human Development, Duke University Medical Center

Copyright © 2005